J. Lindsay

J. Gisbert, J. Lindsay, L. Peyrin-Biroulet, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Review article: strategies for the management of chronic unremitting ulcerative colitis

J. Lindsay, A. Silver, S. Mehta, 2013, Alimentary pharmacology & therapeutics.

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

A. Hart, S. Bloom, J. Lindsay, 2018, Inflammatory bowel diseases.

W1235 Efficacy of Methotrexate in Crohns Disease Patients Previously On Thiopurine Therapy

S. McCartney, S. Bloom, J. Lindsay, 2008 .

Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland

C. O'Morain, A. Hart, J. Lindsay, 2010, European journal of gastroenterology & hepatology.

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

M. Dubinsky, D. Rubin, G. D'Haens, 2022, The Lancet.

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

B. Sands, J. Lindsay, G. Chan, 2019, Alimentary pharmacology & therapeutics.

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

Fraser Cummings, S. Simoens, J. Jeong, 2021, mAbs.

Inflammatory bowel disease in young patients: challenges faced by black and minority ethnic communities in the UK.

A. Poullis, A. Nash, J. Lindsay, 2015, Health & social care in the community.

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy.

J. Lindsay, W. Reinisch, J. Panés, 2019, Journal of Crohn's & colitis.

A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease

J. Lindsay, T. Orchard, C. Wheeler, 2013, Alimentary pharmacology & therapeutics.

Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease

J. Lindsay, R. Feakins, A. Minicozzi, 2022, Clinical science.

GUT-SELECTIVE BIOLOGIC THERAPY FOR ULCERATIVE COLITIS: LESSONS FROM SCIENCE AND PRACTICE

J. Lindsay, L. Peyrin-Biroulet, W. Sandborn, 2015 .

Health‐economic analysis: cost‐effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults

J. Lindsay, G. Chung‐Faye, Y. Punekar, 2008, Alimentary pharmacology & therapeutics.

Medical management of diverticular disease: the role of bulking agents

J. Lindsay, 2006 .

DUOX2 and DUOXA2 Form the Predominant Enzyme System Capable of Producing the Reactive Oxygen Species H2O2 in Active Ulcerative Colitis and are Modulated by 5-Aminosalicylic Acid

R. Poulsom, A. Jubb, J. Lindsay, 2014, Inflammatory bowel diseases.

Systematic review: the financial burden of surgical complications in patients with ulcerative colitis

J. Lindsay, L. Peyrin-Biroulet, A. Bergman, 2015, Alimentary pharmacology & therapeutics.

Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.

J. Lindsay, N. Hawkins, T. Sunderland, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Defects in the adherens junction complex (E-cadherin/ β-catenin) in inflammatory bowel disease

J. Lindsay, A. Silver, A. Nijhuis, 2015, Cell and Tissue Research.

Self‐expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass

J. Lindsay, H. Andreyev, P. Vlavianos, 2004, Alimentary pharmacology & therapeutics.

Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine

S. McCartney, S. Bloom, J. Lindsay, 2009, Alimentary pharmacology & therapeutics.

Improving Food-Related Quality of Life in Inflammatory Bowel Disease through a Novel Web Resource: A Feasibility Randomised Controlled Trial

K. Whelan, M. Lomer, J. Lindsay, 2022, Nutrients.

Anti-TNFS More Frequently Stopped Due to Loss of Response in British Asians with Crohn's Disease: A Single Centre Retrospective Analysis

O. Ahmad, J. Lindsay, B. Cooper, 2017 .

UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care

R. Russell, D. Gaya, S. McCartney, 2017, Gut.

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease

J. Sanderson, J. Lindsay, J. Duley, 2008, Alimentary pharmacology & therapeutics.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.

Laurent Beaugerie, Herbert Tilg, H. Tilg, 2013, Journal of Crohn's & colitis.

Emulsifiers Impact Colonic Length in Mice and Emulsifier Restriction is Feasible in People with Crohn’s Disease

K. Whelan, M. Rossi, J. Lindsay, 2020, Nutrients.

Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect.

K. Whelan, J. Lindsay, G. Parkes, 2014, Journal of Crohn's & colitis.

Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial.

J. Satsangi, J. Gribben, S. Vermeire, 2015, JAMA.

Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial

K. Whelan, M. Lomer, J. Lindsay, 2017, Journal of Crohn's & colitis.

HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants

M. Tremelling, M. Parkes, C. Lees, 2014, Nature Genetics.

Probiotic and prebiotic use in patients with inflammatory bowel disease: A case‐control study†

J. Sanderson, K. Whelan, J. Lindsay, 2010, Inflammatory bowel diseases.

Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials

K. Whelan, J. Lindsay, C. Hedin, 2007, Proceedings of the Nutrition Society.

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results

S. Vermeire, P. Higgins, J. Lindsay, 2023, Inflammatory bowel diseases.

Prebiotic fructans have greater impact on luminal microbiology and CD3+ T cells in healthy siblings than patients with Crohn's disease: A pilot study investigating the potential for primary prevention of inflammatory bowel disease.

K. Whelan, P. Louis, S. McCartney, 2021, Clinical nutrition.

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

Samuel E. Jones, M. Rivas, M. Daly, 2019, JAMA.

AssociationofGeneticVariantsinNUDT15WithThiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

M. Rivas, M. Daly, R. Xavier, 2019 .

Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota*

S. Ng, A. Forbes, N. Prescott, 2012, Inflammatory bowel diseases.

Evolutionary history of human colitis-associated colorectal cancer

Marc J. Williams, P. Martinez, I. Tomlinson, 2018, Gut.

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.

M. Parkes, C. Lees, J. Mansfield, 2019, The lancet. Gastroenterology & hepatology.

Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention

K. Whelan, J. Lindsay, A. Stagg, 2011, Gut.

Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT

B. Sharrack, Hyun-Dong Chang, M. Mohty, 2021, Frontiers in Oncology.

Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings

Trevor Murrells, Kevin Whelan, Natalie J Prescott, 2014, Gut.

Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics.

Matthias Scholz, K. Whelan, F. Fava, 2020, Clinical nutrition.

Adolescents with IBD: the importance of structured transition care.

J. Lindsay, J. Goodhand, N. Croft, 2011, Journal of Crohn's & colitis.

New Therapeutic Strategies

J. Lindsay, K. Kok, A. Ibarra, 2019, Inflammatory Bowel Disease Nursing Manual.

Inhibition of NF-κB Signaling in Human Dendritic Cells by the Enteropathogenic Escherichia coli Effector Protein NleE

J. Lindsay, G. Warnes, T. Macdonald, 2010, The Journal of Immunology.

Low Serum Levels of MicroRNA-19 Are Associated with a Stricturing Crohn's Disease Phenotype

James C. Lee, J. Lindsay, A. Di Sabatino, 2015, Inflammatory bowel diseases.

Intestinal Fibrosis in Crohn's Disease: Role of microRNAs as Fibrogenic Modulators, Serum Biomarkers, and Therapeutic Targets

J. Lindsay, A. Silver, R. Feakins, 2015, Inflammatory bowel diseases.

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease

M. Parkes, C. Lees, J. Satsangi, 2016 .

Effects of Low-FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.

F. Levenez, N. Pons, S. Ehrlich, 2019, Gastroenterology.

Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis

F. Brennan, J. Lindsay, H. Hodgson, 2003, Gut.

10 production and is therapeutic for murine colitis murine interleukin 10 induces colonic interleukin Local delivery of adenoviral vectors encoding

F. Brennan, J. Lindsay, H. Hodgson, 2003 .

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.

S. Vermeire, S. Travis, G. Van Assche, 2012, Journal of Crohn's & colitis.

Lyndsay D. Hughes, K. Whelan, M. Morgan, 2016, Journal of Crohn's & colitis.

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients

M. Parkes, C. Lees, J. Satsangi, 2014, Alimentary Pharmacology and Therapeutics.

Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey

S. Vermeire, M. Bayliss, D. Rubin, 2018, Journal of Crohn's & colitis.

Surgery in young adults with inflammatory bowel disease: a narrative account.

D. Gould, D. Kelly, J. Lindsay, 2013, International journal of nursing studies.

The cation channel TRPM8 influences the differentiation and function of human monocytes

W. Lee, J. Lindsay, L. Blackshaw, 2022, Journal of leukocyte biology.

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis.

M. Silverberg, L. Stitt, S. Travis, 2018, Gastrointestinal endoscopy.

[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)].

S. Vermeire, S. Travis, G. Van Assche, 2014, Revista de gastroenterologia de Mexico.

Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

S. Ng, C. O'Morain, A. Griffiths, 2022, The Lancet Gastroenterology & Hepatology.

Ulcerative Colitis: Shifting Sands

G. D'Haens, J. Lindsay, R. Panaccione, 2019, Drugs in R&D.

Inflammatory bowel disease in young people: The case for transitional clinics

J. Lindsay, J. Goodhand, M. Wahed, 2010, Inflammatory bowel diseases.

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

M. Parkes, J. Satsangi, Fraser Cummings, 2023, The lancet. Gastroenterology & hepatology.

Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease

J. Lindsay, D. Rampton, P. Irving, 2012, Journal of pediatric gastroenterology and nutrition.

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

S. Vermeire, P. Higgins, G. D'Haens, 2022, The Lancet.

DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open

B. Sands, J. Lindsay, G. Chan, 2018 .

Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres.

S. Ng, A. Hart, J. Lindsay, 2013, Journal of Crohn's & colitis.

In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts.

R. Poulsom, G. Corazza, J. Lindsay, 2014, Clinical science.

OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study

S. Vermeire, G. D'Haens, J. Lindsay, 2021, Journal of Crohn's & Colitis.

P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance

J. Lindsay, J. Panés, Y. Sanchez Gonzalez, 2022, Journal of Crohn's and Colitis.

Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease.

C. K. Yao, M. Silverberg, A. Ananthakrishnan, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

ECCO IBD Curriculum.

J. Lindsay, J. Panés, P. Irving, 2017, Journal of Crohn's & Colitis.

Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD.

J. Gribben, J. Cavenagh, J. Lindsay, 2020, Blood.

Stem Cell Transplantation for Refractory Crohn Disease--Reply.

J. Gribben, C. Hawkey, J. Lindsay, 2016, Journal of the American Medical Association (JAMA).

Autologous Stem Cell Transplantation for Refractory Crohn's Disease: Is it Time to Take a Long-Term View?

J. Lindsay, 2017, Journal of Crohn's & colitis.

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.

K. Whelan, P. Louis, F. Fava, 2017, Gastroenterology.

Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome

Kevin Whelan, Chris Probert, K. Whelan, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

M. Parkes, C. Lees, T. Ahmad, 2021, The Lancet Gastroenterology & Hepatology.

The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients

E. Giannoulatou, J. Lindsay, Kriti Singh, 2017, PloS one.

OC-004 Thiopurine Induced Pancreatitis In Inflammatory Bowel Disease: Clinical Features And Genetic Determinants

T. Ahmad, A. Holden, J. Lindsay, 2014, Gut.

Structured Transition Enhances Clinical Outcome without an Increase in Healthcare Cost in Adolescent Patients with IBD: the UK Transit Study

R. Russell, D. Gaya, S. McCartney, 2017 .

P207 - Infliximab use in adolescents with IBD

J. Lindsay, J. Goodhand, N. Croft, 2009 .

Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force

C. O'Morain, G. Kaplan, J. Lindsay, 2020, Journal of Crohn's & colitis.

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

J. Satsangi, P. Klenerman, P. Simmonds, 2021, Gut.

Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England

J. Walters, A. Hart, J. Lindsay, 2009, Alimentary pharmacology & therapeutics.

Barriers to transition care in inflammatory bowel disease: a survey of adult and paediatric gastroenterologists in the UK

R. Russell, S. McCartney, S. Sebastian, 2011, Gut.

Epithelial down‐regulation of the miR‐200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition

J. Lindsay, A. Di Sabatino, P. Biancheri, 2018, Journal of cellular and molecular medicine.

Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease?

J. Lindsay, H. Hodgson, 2001, Alimentary pharmacology & therapeutics.

Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms

K. Whelan, J. Lindsay, Ö. Eyice, 2021, Nutrients.

Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease

J. Lindsay, T. Macdonald, A. Stagg, 2016, Mucosal Immunology.

Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease

J. Lindsay, H. Andreyev, C. Shaw, 2014, Frontline Gastroenterology.

1133 The Low FODMAP Diet Reduces Symptoms in Irritable Bowel Syndrome Compared With Placebo Diet and the Microbiota Alterations May Be Prevented by Probiotic Co-Administration: A 2x2 Factorial Randomized Controlled Trial

K. Whelan, P. Louis, H. Staudacher, 2016 .

800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve Study

J. Lindsay, W. Sandborn, E. Loftus, 2019, Gastroenterology.

Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial

K. Pennert, H. Gage, J. Lindsay, 2013, The Lancet.

Food additive emulsifier restriction is feasible in people with Crohn's disease

K. Whelan, M. Rossi, J. Lindsay, 2020, Proceedings of the Nutrition Society.

Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply

B. Sands, J. Lindsay, G. Chan, 2020, Alimentary pharmacology & therapeutics.

The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease

K. Whelan, J. Lindsay, C. J. van der Gast, 2017, Gut microbes.

Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.

J. Lindsay, V. Jairath, Zheng-Yi Zhou, 2023, Inflammatory bowel diseases.

Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research

M. Parkes, C. Lees, J. Satsangi, 2023, Gut.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies

S. Vermeire, M. Bayliss, D. Rubin, 2018, Journal of Crohn's & colitis.

775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study

D. Rubin, G. D'Haens, J. Lindsay, 2021, Gastroenterology.

Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)

R. Prescott, C. Lees, J. Satsangi, 2023, Cellular and molecular gastroenterology and hepatology.

Familial adenomatous patients with desmoid tumours show increased expression of miR-34a in serum and high levels in tumours

C. Yau, E. Giannoulatou, J. Lindsay, 2016, Oncoscience.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.

H. Tilg, A. Forbes, C. O'Morain, 2010, Journal of Crohn's & colitis.

Volatile organic compounds predict response to both low FODMAP diet and probiotics in irritable bowel syndrome: a randomised controlled trial

K. Whelan, H. Staudacher, M. Rossi, 2017, Proceedings of the Nutrition Society.

Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.

J. Satsangi, M. Silverberg, S. Vermeire, 2023, Inflammatory bowel diseases.

Siblings of patients with Crohn’s disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities

K. Whelan, S. McCartney, J. Lindsay, 2015, Gut.

Establishment of a validated central reading system for ileocolonoscopy in an academic setting

M. Parkes, S. Travis, N. Kennedy, 2022, Gut.

Living with Crohn’s disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study)

C. Hawkey, J. Lindsay, Joanne Cooper, 2017, BMJ Open.

Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans.

C. Yau, R. Poulsom, E. Giannoulatou, 2017, Inflammatory bowel diseases.

Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients

M. Colombo, J. Lindsay, A. Armuzzi, 2020, Cellular and molecular gastroenterology and hepatology.

Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases

J. Lindsay, A. Armuzzi, C. Felice, 2015, Alimentary pharmacology & therapeutics.

Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis : Definitions and diagnosis

S. Travis, R. Eliakim, J. Lindsay, 2012 .

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease

A. Forbes, K. Whelan, M. Kamm, 2005, Gut.

Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease

J. Juarez, J. Lindsay, S. Mehandru, 2023, Mucosal immunology.

[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)].

S. Vermeire, S. Travis, R. Eliakim, 2014, Revista de gastroenterologia de Mexico.

[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)].

S. Travis, M. Sans, J. Lindsay, 2015, Revista de gastroenterologia de Mexico.

[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)].

G. Rogler, S. Travis, P. Gionchetti, 2015, Revista de gastroenterologia de Mexico.

Evolutionary history of human colitis-associated colorectal cancer

Marc J. Williams, P. Martinez, I. Tomlinson, 2018, Gut.

P318 Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort

R. Vega, E. Seward, S. McCartney, 2019, Journal of Crohn's & Colitis.

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis

M. Parkes, C. Lees, J. Satsangi, 2016, Alimentary pharmacology & therapeutics.

Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease

J. Satsangi, J. Lindsay, A. Adams, 2022, The Lancet Gastroenterology & Hepatology.

Probiotic and prebiotic use by patients with inflammatory bowel disease

J. Sanderson, K. Whelan, J. Lindsay, 2009, Proceedings of the Nutrition Society.

Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease

S. Ng, A. Forbes, K. Whelan, 2011, Inflammatory bowel diseases.

Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases

J. Lindsay, A. Armuzzi, C. Felice, 2015, Alimentary pharmacology & therapeutics.

Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota*

A. Forbes, N. Prescott, J. Sanderson, 2012, Inflammatory bowel diseases.

Dietary intake of inulin-type fructans in active and inactive Crohn's disease and healthy controls: a case-control study.

A. Forbes, K. Whelan, A. Hart, 2015, Journal of Crohn's & colitis.

Review article: strategies for the management of chronic unremitting ulcerative colitis

J. Lindsay, A. Silver, Shameer Mehta, 2013, Alimentary pharmacology & therapeutics.

Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease

J. Lindsay, D. Rampton, J. Goodhand, 2012, Inflammatory bowel diseases.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

S. Vermeire, S. Travis, M. Sans, 2012, Journal of Crohn's & colitis.

Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

S. Travis, M. Sans, J. Lindsay, 2012 .

Thiopurine methyl transferase activity predicts both toxicity and clinical response to azathioprine in inflammatory bowel disease: The London IBD forum prospective study

J. Sanderson, J. Lindsay, J. Duley, 2004 .

Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn's disease.

J. Lindsay, A. Stagg, T. Sanders, 2014, Gastroenterology.

W1312 Long Term Efficacy of the Second Biologic in the Management of Crohn's Disease. A Retrospective Survey on an English- Irish Cohort

C. O'Morain, J. Lindsay, S. O’Donnell, 2010 .

In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts.

R. Poulsom, G. Corazza, J. Lindsay, 2014, Clinical science.

OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies

M. Ferrante, J. Lindsay, S. Schreiber, 2023, Journal of Crohn's and Colitis.

Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.

C. Lees, D. Gaya, J. Lindsay, 2023, Inflammatory bowel diseases.